60 ml tirzepatide / Niacinamide Injection Tirzepatide Injection (Pre-filled Syringe) |

Emerging data suggest that glucagonlike peptide1 receptor agonists (GLP1 RAs), originally developed for glycemic control and weight management, may have direct hepatic benefits even in patients who are not visibly obese or overtly diabetic

Your safety and well-being are always our top priority, and any long-term treatment plan is created with that in mind

Long-Term Health Considerations Low blood pressure, also known as hypotension, can have various long-term effects on overall health

OSA evaluation was available in 69 participants, of whom 71.4% were finally diagnosed (59.1% experienced mild, 34.6% moderate, and 6.1% severe OSA)

Most shedding linked to GLP-1 medicines appears to be telogen effluvium tied to rapid weight loss, which tends to recover once weight stabilizes and any nutrient gap is corrected

Diabetes Australia Research Program, Grant/Award Number: Y22GShiY DATA AVAILABILITY STATEMENT The data that support the findings of this study are available on request from the corresponding author